Oncology focus
Latest in Oncology
ArticleAI builds dual-action cancer drug targeting PKMYT1
Research published in Nature Communications shows how generative AI can be used to design complex dual-action cancer drug candidates. Insilico Medicine has developed a PKMYT1 degrader that both eliminates the target protein and blocks its activity, demonstrating the growing role of AI in advanced drug discovery.
ArticleImproving selectivity in antibody–drug conjugates
Promatix Biosciences is developing a new generation of bispecific antibody–drug conjugates using proprietary membrane proteomics data to identify highly selective target pairings. CEO Dr Michael Hunter explains how the company’s TXPro database enables discovery of previously unexplored tumour biology to improve therapeutic index and reduce on-target/off-tumour toxicities in solid tumours.
NewsEli Lilly acquires CrossBridge Bio’s dual-payload ADC platform
Eli Lilly has acquired CrossBridge Bio, advancing a dual-payload antibody-drug conjugate platform developed at UTHealth Houston. The technology aims to deliver chemotherapy more precisely to tumour cells whilst minimising damage to healthy tissue, with lead candidate CBB-120 now positioned for accelerated clinical development.
Featured
AI builds dual-action cancer drug targeting PKMYT1
Research published in Nature Communications shows how generative AI can be used to design complex dual-action cancer drug candidates. Insilico Medicine has developed a PKMYT1 degrader that both eliminates the target protein and blocks its activity, demonstrating the growing role of AI in advanced drug discovery.
Improving selectivity in antibody–drug conjugates
Promatix Biosciences is developing a new generation of bispecific antibody–drug conjugates using proprietary membrane proteomics data to identify highly selective target pairings. CEO Dr Michael Hunter explains how the company’s TXPro database enables discovery of previously unexplored tumour biology to improve therapeutic index and reduce on-target/off-tumour toxicities in solid tumours.
Anticipating adaptation: understanding and overcoming cancer drug resistance
Neil Bhowmick explores how understanding the mechanisms of cancer drug resistance has reframed our approach to treatment, revealing containment and control as realistic goals for therapeutic strategies.
More Oncology
AI builds dual-action cancer drug targeting PKMYT1
Research published in Nature Communications shows how generative AI can be used to design complex dual-action cancer drug candidates. Insilico Medicine has developed a PKMYT1 degrader that both eliminates the target protein and blocks its activity, demonstrating the growing role of AI in advanced drug discovery.
Improving selectivity in antibody–drug conjugates
Promatix Biosciences is developing a new generation of bispecific antibody–drug conjugates using proprietary membrane proteomics data to identify highly selective target pairings. CEO Dr Michael Hunter explains how the company’s TXPro database enables discovery of previously unexplored tumour biology to improve therapeutic index and reduce on-target/off-tumour toxicities in solid tumours.
Eli Lilly acquires CrossBridge Bio’s dual-payload ADC platform
Eli Lilly has acquired CrossBridge Bio, advancing a dual-payload antibody-drug conjugate platform developed at UTHealth Houston. The technology aims to deliver chemotherapy more precisely to tumour cells whilst minimising damage to healthy tissue, with lead candidate CBB-120 now positioned for accelerated clinical development.
Cells use nanoparticle couriers to exchange biological information
University College Dublin researchers have discovered that cells use nanoparticle-based courier systems coated with proteins and RNA to exchange biological information. The findings detail how natural cellular gateways could be exploited to deliver therapeutic molecules to previously inaccessible locations, potentially changing the way RNA, gene and protein-based therapies work.
Ontario invests $3.1M in next-generation cancer therapeutics
The Ontario Institute for Cancer Research has awarded $3.1 million to four provincial research teams developing novel cancer therapies designed to overcome drug resistance and reduce treatment-related toxicity.
Champions Oncology to present eight studies at AACR 2026
Champions Oncology will present eight studies at AACR 2026 spanning KRAS-mutant tumours, ovarian cancer, glioblastoma and emerging therapies including radiopharmaceuticals and CAR-T, using patient-derived models to improve early-stage decision-making in oncology drug development.
Insilico announces ISM6200 AI-designed drug candidate for ovarian cancer and cortisol disorders
Insilico Medicine has nominated ISM6200, a preclinical drug candidate designed using generative AI to target NR3C1, a receptor involved in cortisol regulation.
Lactylation emerges as key driver of lung cancer resistance
New research from Shanghai Pulmonary Hospital outlines how lactate-driven lactylation acts as a metabolic switch controlling epigenetic regulation in lung cancer. The findings reveal self-reinforcing feedback loops that sustain drug resistance and suggest novel therapeutic strategies targeting the enzymes and pathways that maintain this process.
3D-printed drug carriers deliver chemotherapy directly to tumours
Novel FRESH 3D printing technology enables fabrication of nanoscale spanlastic carriers for localised anticancer drug delivery. Early in vitro studies have demonstrated enhanced cellular uptake and tumour cell killing whilst potentially minimising systemic toxicity associated with conventional chemotherapy administration.
Lipid nanoparticles deliver dual therapy for lung cancer
Oregon State University researchers have developed engineered lipid nanoparticles that deliver follistatin mRNA directly to lung tumours, simultaneously targeting cancer growth and muscle-wasting cachexia in preclinical studies.
Anticipating adaptation: understanding and overcoming cancer drug resistance
Neil Bhowmick explores how understanding the mechanisms of cancer drug resistance has reframed our approach to treatment, revealing containment and control as realistic goals for therapeutic strategies.
Haem signalling pathway identified as key driver of T cell exhaustion
University of Lausanne researchers have identified a molecular mechanism explaining how cancer-fighting T cells become exhausted in tumours, offering a potential route to improve CAR T therapies through proteasome modulation during cell manufacturing.
COPD drug roflumilast may help fight breast cancer lung metastasis
University of Colorado Anschutz Cancer Center scientists have uncovered how metastatic breast cancer cells exploit pulmonary repair pathways to establish tumours in the lungs.
New AI-designed T-cell engager LGTX-101 to be presented at AACR in San Diego
LabGenius Therapeutics will present preclinical data for LGTX-101, its AI-designed Nectin-4 x CD3 T-cell engager, at AACR 2026 in San Diego.
Probiotic bacteria successfully attacks tumours in preclinical models
Engineered probiotic bacteria that can deliver cancer-fighting drugs directly to tumours have shown promising results in mice, offering a potential new approach to targeted cancer therapy.
SonoPIN ultrasound method shows promise for targeted cancer therapy
A new ultrasound-based technique developed by researchers at Duke University uses microbubbles to deliver cancer drugs directly into tumour cells, showing promise for highly targeted treatments that cause minimal damage to healthy tissue.